When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani ...

Billed as nonaddictive, new pain pill could soon win FDA approval. Questions remain about whether the non-opioid drug developed by Vertex Pharmaceuticals could be effective for chronic pain.

The Food and Drug Administration approved Vertex Pharmaceuticals' non-opioid painkiller pill, a new alternative for pain relief that comes without the risk of addiction. It's a milestone after a ...

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries.

The Food and Drug Administration on Thursday approved Journavx, a non-opioid painkiller that is the first novel pain drug to win government authorization in more than 20 years. Vertex ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best biotech stocks to invest in now. On June 20, Vertex ...

Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 10 years ago, it would be worth $345.57 today based on a price of $445.20 for VRTX at the time of writing.

WASHINGTON (AP) — Federal ... The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries.

We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had been up well over 20% year to date. The main bad news with Vertex's Q1 ...

One-year data suggest allogeneic stem cell-derived islet-cell therapy could become a future option for those with type 1 ...